News | November 15, 2022
Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher
The company sees the business reaching $100mn
The company sees the business reaching $100mn
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue from operations up 26% to Rs. 768 crores
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Subscribe To Our Newsletter & Stay Updated
